Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Anthony L. Boral
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Related publications
Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
Cancer
Cancer Research
Oncology
Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
British Journal of Haematology
Hematology
Therapy With Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Final Results of a Phase II Trial (CALGB 50501)
Leukemia and Lymphoma
Cancer Research
Oncology
Hematology
Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Efficacy of Subcutaneous Bortezomib in the Management of Patients With Multiple Myeloma or Relapsed Mantle Cell Lymphoma
Clinical Medicine Insights: Therapeutics
Medicine
Pharmacology
Pharmaceutical Science
Outcomes in First Relapsed-Refractory Younger Patients With Mantle Cell Lymphoma: Results From the Mantle-First Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
